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Abstract
There is some evidence that early colonization of the intestine affects the composition of the intestinal microbiota
after weaning. In the present study, the effect of prebiotics administered from the first day of life on fecal counts of
bifidobacteria and lactobacilli were studied during and after the administration of the prebiotics. In this double-blind,
randomized, placebo-controlled, explorative study, 20 newborns of hepatitis C virus-infected mothers who decided not to
breast feed due to their concerns regarding their plasma viral loadwere randomly assigned to either a formulawith 8 g/L of a
specific prebiotic mixture (short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides, ratio 9:1) or a
formula containing the same amount of maltodextrin (placebo). Clinical examination including anthropometric measure-
ments, microbiological analysis of fecal samples, and blood leukocyte population analysis were performed at birth and 3, 6,
and 12mo age. At the age of 12mo, hepatitis B vaccine-specific IgG serum titers (Hepatitis B virus surface antibodies)were
also measured. Prebiotic supplementation resulted in more fecal bifidobacteria (P , 0.0001) and lactobacilli (P = 0.0044)
compared with the placebo group. These differences between the groups were maintained during the second half of
the first yearwithout any prebiotic supplementation. Therewas no influence of the different diets on anthropometric data or
the measured immunological variables. The data from this small explorative study indicate that early colonization of the
intestine might have long-lasting effects on the composition of the intestinal microbiota. J. Nutr. 141: 1335–1339, 2011.
Introduction
There is increasing evidence that the intestinal microbiota plays
a crucial role in postnatal development of the immune system
(1–3). There is broad consensus that breastfeeding is essential
and is the best option for optimal development of the intestinal
microbiota, resulting in a healthy and balanced immune system
(2). Consequently, many attempts have been made to influence
the intestinal microbiota composition of bottle-fed infants
toward that found during breastfeeding. Most of these experi-
ences exist for prebiotics (4,5) and probiotics (6). More recently,
a combination of both, so-called synbiotics (7) or fermented
milk (8,9), have also been used as potential treatments to achieve
a bifidogenic effect in formula-fed infants.
Oligosaccharides are the main prebiotic factor in humanmilk
(10–13). Because their structure is very complex, they are not yet
available for the production of infant formulas. Thus, research
activities have focused on the development of nonhuman milk
oligosaccharides as an alternative (14). Several compounds of
different structures have been identified and investigated (5).
Since 2002, several infant formulas containing a specific
mixture of short-chain galacto-oligosaccharides (scGOS)7 and
long-chain fructo-oligosaccharides (lcFOS) have been on the
market (15). Studies in infants with a familial history of atopy/
allergy fed such prebiotic formulae demonstrated a reduced risk
of atopic dermatitis accompanied by an antiallergic antibody
profile in plasma (16,17). Similarly, antiallergic effects have been
demonstrated in animals sensitized with ova albumin (18) or
cow milk proteins (19,20). In these latter animal studies, it was
demonstrated that so-called regulatory T-cells were involved
(20), indicating that the inhibition of allergic symptoms were not
only due to Th2 damping and/or Th1 stimulation. In addition,
a reduction in infectious episodes was observed in infants at risk
of developing allergy/atopy (21) as well as in those without such
risk (22). In summary, the experimental data (23) as well as the
results of studies in humans (5) suggest an immune-modulating
effect of this prebiotic mixture (24).
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For ethical reasons, a certain period of breastfeeding has to be
accepted. Because the early imprinting of intestinal microbiota is
heavily influenced by early breastfeeding (25), it was of
particular interest to obtain data from infants fed the formula
from the first day of life. Particular interest was given to the
weaning period and the second half of the first year of life to
evaluate the stability of the fecal counts of bifidobacteria and
lactobacilli after intervention.
In addition, there is still a debate about which biomarkers are
really relevant for the evaluation of a normal balanced “healthy”
immune system (26). As explorative biomarkers, leukocyte popula-
tions and lymphocyte subpopulations, total IgE levels, and hepa-
titis B virus antibody titers in response to hepatitis B vaccination
were examined in this group of infants.
Therefore, this explorative study was initiated to evaluate the
influence of a specific prebiotic mixture administered from the
first day of life on the development of intestinal microbiota in
formula-fed infants with a focus on fecal counts of bifidobacteria
and lactobacilli during and after intervention with prebiotics;
the above-mentioned explorative immune parameters were also
examined.
Materials and Methods
Study population and methods. This randomized, placebo-controlled,
double-blinded trial was conducted at the Pediatric Department of the San
PaoloHospital inMilan between January 2002 andDecember 2005. Infants
born from hepatitis C virus (HCV)-infected mothers were eligible for the
study. Although it is not the policy of the hospital to recommend formula
feeding in these cases, some mothers decided not to breastfeed due to their
concerns regarding the relevant plasma HCV viral load before delivery.
The study was approved by the San Paolo Hospital Ethical Committee
and written informed consent was obtained from all parents of all enrolled
infants.
Inclusion criteria were a gestational age between 37 and 42 wk, a birth
weight appropriate for gestational age, and exclusive formula feeding from
the first day of life. Prematurity, breastfeeding, major malformations, and
HCV infection were exclusion criteria.
Infants who developed metabolic, endocrinologic, and immuno-
logic disorders, lactose intolerance and/or allergy to cow’s milk as well
as assumption of other pre- or probiotics were planned to be excluded
from the study.
The infants were tested for exclusion of vertical HCV infection at
birth and at the age of 1 mo. Two negative results of measurement of
qualitative plasma HCV viral load were the basis to exclude vertical
HCV infection (27).
The infants were randomly assigned to receive a regular bovine
milk formula (Aptamil, Milupa) either supplemented with 8 g/L pre-
biotics or a similar quantity of maltodextrin as placebo (Milupa) from
birth to 6 mo of life. During the second half-year of life, the infants
received regular bovine milk-based, follow-on formula without any
supplementation.
The prebiotic mixture used in the study consisted of scGOS derived
from enzymatic synthesis from lactose and lcFOS separated from
chicory inulin in a ratio of 9:1 (15).
The infants underwent clinical examination at birth and 3, 6, and
12 mo of age. During this examination, anthropometric measurements
(weight, length, head circumference) using standard methods (28) and a
medical examination were performed. Clinical data concerning infections
or antibiotic treatments during the month before each medical examina-
tion were registered. Fecal samples were obtained for measurements of
counts of bifidobacteria and lactobacilli as well as fecal pH.
Additionally, 2 mL venous blood was obtained for routine analysis of
leukocyte populations and plasma total IgE titers. At the end of the study,
an extra 1 mL blood was obtained for measurement of anti-hepatitis B
virus surface specific antibody serum titers (1 mo after the 3rd vaccine
dosage was administered).
Fecal counts of bifidobacteria and lactobacilli were measured as
previously described (29). Fecal pH was measured by using a Handylab
pHmeter (Schott Glas) equipped with an Inlab 423 pH electrode (Mettler-
Toledo).
Immunophenotyping of peripheral blood lymphocyte T cell subsets
was performed by multiparameter flow cytometry on a FACScan flow
cytometer (Becton Dickinson).
The IgE titer and specific IgG anti HBs-antigen titer were measured by
Electro-Chemi-Luminescence Immuno Assay (ECLIA, Roche Diagnostics).
Statistics. The results were analyzed on a per protocol basis. Time-
balanced randomization was performed with the software RANCODE
(IDV Gauting) with a random permuted block size of 4. Data were
compared between the 2 formula groups by 2-sided Mann-Whitney U
test. For analysis of the fecal counts of bifidobacteria and lactobacilli as
the primary outcomes, 95% CI of the mean were calculated using the
Wilson score method for each time point. P , 0.05 (2-tailed) was
considered significant. Data are presented as mean 6 SD or mean (95%
CI). The statistical analysis was performed using SAS (SAS Enterprise
Guide 4.1) for Windows (SAS Institute).
Results
Twenty of 22 enrolled infants completed the study. One infant
(placebo group) failed due to noncompliance and 1 infant discon-
tinued the follow-up for unknown reasons (prebiotic group).
At enrollment, the 2 groups did not differ in terms of mode of
delivery, gestational age, gender, weight, length, or head cir-
cumference at birth (Table 1).
All infants had a normal weight gain, length growth, and
head circumference increment, and there were no differences
between the groups for all measurements (Table 2). None of the
infants underwent any antibiotic treatment or suffered from
any clinically relevant infection during the month before each
evaluation.
The prebiotic supplementation influenced the number of bi-
fidobacteria and lactobacilli in the feces (P, 0.005). The counts
of bifidobacteria and lactobacilli increased during the first 3 mo
in both groups (P , 0.0001) and remained stable afterwards
(P. 0.05). Starting from the 3 mo of age evaluation, the counts
of both bifidobacteria and lactobacilli were higher in the
prebiotic group (P , 0.013). This difference persisted even
after discontinuation of the prebiotic supplementation at 7 mo
of age (Fig. 1; Table 2).
There was an influence of the supplementation on fecal pH
(P = 0.0005), with significantly higher pH values in the control
group (Table 2). Except for lymphocyte T CD3+ titers at 12 mo
of age, which were lower in the control group (P = 0.017), the
groups did not differ at each evaluation in the measured
leukocyte populations (Supplemental Table 1). The total IgE
TABLE 1 Baseline characteristics of the infants that
completed the study1
Prebiotic group Control group
n (M/F) 10 (5/5) 10 (2/8)
Vaginal delivery, n 10 10
Gestational age, wk 39.1 6 0.8 39.1 6 1.3
Weight at birth, kg 3.32 6 0.7 3.29 6 0.34
Length at birth, cm 50.2 6 2.7 51.2 6 1.9
Head circumference at birth, cm 33.4 6 0.9 33.9 6 1.0
Bifidobacteria, CFU/g stool 5.5 (4.8–6.3) 5.6 (5.0–6.3)
Lactobacilli, CFU/g stool 4.6 (4.0–5.2) 4.8 (4.2–5.4)
1 Data are mean 6 SD or mean (95% CI).
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titers increased from 3 mo of age to the end of the study (P =
0.03). The diet did not influence the IgE levels in serum (P =
0.27). At 12 mo of age, the anti-hepatitis B virus surface
antibody titers did not differ between the feeding groups (data
not shown). Both formulas were well tolerated with no adverse
effects recorded.
Discussion
In this study, the prebiotic mixture of scGOS:lcFOS in a ratio of
9:1 significantly increased numbers of fecal bifidobacteria and
lactobacilli, as found in several studies (5). The interesting finding
in this study is that the early imprinted intestinal microbiota re-
mained relatively stable even after weaning. This is in line with a
study using classical microbiological techniques (30) as well as a
study performed with molecular-based methods (31). Both studies,
as in the present study, demonstrated a substantial stability of bi-
fidobacteria after weaning, confirming data from the early 1980s
(32).
Apart from the early imprinting of the intestinal microbiota,
the genotype of the host could have an important impact on the
stability of the intestinal ecosystem as well (33). The present
study did not allow us to conclude whether early imprinting or
other factors play a role in the observed stability of the number
of fecal bifidobacteria and lactobacilli. The hypothesis that the
early colonization might have an effect is supported by the ob-
servation that differences in early colonization between infants
born by caesarean and vaginal delivery (34) can have long-lasting
effects as well (35,36). A similar observation was reported by
Jernberg et al. (37) in infants treated with antibiotics. The impact
of the treatment persisted up to 2 y. Furthermore, Roger et al. (38)
reported a greater diversity of Bifidobacterium populations in
breast-fed than in formula-fed infants, an effect persisting up to
18 mo of age. On the other hand, Rinne et al. (39) studied the
effect of early administration of probiotics and could not find
any significant interference with composition or quantity of gut
microbiota.
In the present study, only culturing methods were used to
quantify bifidobacteria and lactobacilli, which is a limitation of
the study (40). However, direct comparison of the technique
used in the study with the FISH technique demonstrated nearly
similar results at a concentration of 8 g prebiotics/L formula
(24).
In animal experiments (19), the scGOS:lcFOS mixture has
shown immune modulation capacity. These experimental data are
in line with the observation that in infants with a familiar history
of atopy/allergy, the same prebiotic mixture induced a significant
reduction in allergy-related symptoms at 6 mo of age (17). This
effect was still seen at an age of 2 y (41), indicating an immune-
modulating and -imprinting capacity of the prebiotics used.
In the present study, there was no effect on different leukocyte
populations that might indicate that these parameters are not
suitable to investigate developmental aspects of the immune sys-
tem. Raes et al. (42) also found no significant effect of the same
prebiotic mixture on basal blood immune variables. However, in
TABLE 2 Formula consumption, weight, length, head
circumference, fecal pH, and fecal counts of
bifidobacteria and lactobacilli in infants that
received prebiotic or control formula from
birth to 6 mo of age1
Age and Item Prebiotic group Control group P
3 mo
Formula, mL/d 767 6 145 779 6 71.4 0.87
Weight, kg 6.15 6 0.81 6.27 6 0.71 0.82
Length, cm 63.1 6 2.9 62.1 6 2.4 0.88
Head circumference, cm 39.6 6 2.8 40.6 6 1.3 0.36
Bifidobacteria, CFU/g stool 9.1 (8.7–9.5) 6.4 (5.8–7.0) 0.0014
Lactobacilli, CFU/g stool 6.7 (6.1–7.3) 5.2 (4.6–5.9) 0.0125
Fecal pH 5.24 6 0.32 6.25 6 0.51 0.0006
6 mo
Formula, mL/d 622 6 223 654 6 234 0.94
Weight, kg 8.99 6 0.85 7.97 6 1.03 0.47
Length, cm 69.0 6 2.6 69.0 6 3.1 0.88
Head circumference, cm 43.2 6 1.0 43.4 6 1.4 0.59
Bifidobacteria, CFU/g stool 9.4 (8.9–10.0) 7.3 (6.9–7.7) 0.0014
Lactobacilli, CFU/g stool 6.9 (6.3–7.5) 5.5 (5.0–6.0) 0.0054
Fecal pH 5.15 6 0.39 6.19 6 0.54 0.0011
12 mo
Formula, mL/d 310 6 105 374 6 156 0.44
Weight, kg 10.9 6 1.26 9.78 6 1.21 0.08
Length, cm 78.5 6 4.2 77.4 6 5.0 0.42
Head circumference, cm 46.0 6 1.0 46.9 6 1.9 0.30
Bifidobacteria, CFU/g stool 8.9 (8.6–9.3) 7.1 (6.8–7.4) 0.0016
Lactobacilli, CFU/g stool 6.7 (6.2–7.2) 5.4 (5.1–5.8) 0.0042
Fecal pH 5.88 6 0.33 6.20 6 0.58 0.30
1 Data are mean 6 SD or mean (95% CI).
FIGURE 1 Bifidobacteria (A) and lactobacilli (B) counts in fecal
samples from infants that received prebiotic or control formula from
birth to 6 mo of age. Data are shown in box plots (medians and 95%
CI), n = 10.
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the same cohort, fecal secretory IgA titer was significantly higher in
infants fed the supplemented formula (43), indicating an effect of
the specific prebiotic mixture on the mucosal immune system.
The vaccine-specific antibody production or T cell function
are classified as markers with high suitability in terms of bio-
logical relevance, sensitivity, and practical feasibility (26). In the
present study, no influence of the prebiotic supplement on hepa-
titis B vaccination response could be observed. This might be
partially related to methodological aspects such as the optimal
timing to measure vaccination response during infancy. The vac-
cine response is very robust. For this reason, subtle effects induced
by prebiotic diets might be difficult to detect. If the infants were
vaccinated using suboptimal vaccination protocols as is done in
animal models (18), it might be possible to demonstrate vaccina-
tion improvement. For ethical reasons, suboptimal vaccination in
infants is not possible.
More clinical trials are needed to identify predictive bio-
markers in human infants that describe the development of the
immune system. One example might be Ig-free light chain, which
predicts several immune disorders in humans, including infants.
Very recent data already indicate that this biomarker can be
analyzed easily in plasma from infants and that this biomarker
predicts the onset of allergic disorders such as atopic dermatitis,
which can significantly be affected by the prebiotic diet. Thus, in
future studies, these new biomarkers for immune development
should be analyzed (20).
In summary, the data from this small explorative study in-
dicate that early colonization of the intestine might have long-
lasting effects on the composition of the intestinal microbiota.
This must be confirmed in larger studies additionally using mole-
cular techniques of characterization of intestinal microbiota.
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